Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Bevacizumab Does Not Inhibit the Formation of Liver Vessels and Liver Regeneration Following Major Hepatectomy: A Large Animal Model Study

O. Troup, A. Skalicky, L. Vistejnova, P. Klein, A. Maleckova, B. Florova, T. Malkus, J. Molacek, V. Treska, M. Kriz, J. Zeman, T. Skalicky

. 2022 ; 36 (3) : 1083-1094. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018572

BACKGROUND/AIM: Patients with unresectable liver colorectal cancer metastases are treated with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing the mass of metastases and thus increasing the chances of resectability. Bevacizumab comprises an anti-VEGF (vascular endothelial growth factor) humanized IgG monoclonal antibody that is used for biological therapy purposes. It acts to inhibit angiogenesis, thereby slowing down the growth of metastases. Due to its being administered systematically, bevacizumab also exerts an effect on the surrounding healthy liver parenchyma and potentially limits the process of neovascularization and thus regeneration of the liver. Since the remnant liver volume forms an important factor in postoperative morbidity and mortality following a major hepatectomy, we decided to study the effect of bevacizumab on vascular and biliary microarchitecture in healthy liver parenchyma and its ability to regenerate following major hepatectomy. MATERIALS AND METHODS: We performed an experiment employing a large animal model where a total of 16 piglets were divided into two groups (8 piglets in the control group and 8 piglets in the experimental group with bevacizumab). All the animals were subjected to major hepatectomy and the experimental group was given bevacizumab prior to hepatectomy. All the animals were sacrificed after 4 weeks. We performed biochemical analyses at regular time intervals during the follow-up period. Histological examination of the liver tissue was performed following sacrifice of the animals. RESULTS: No statistical difference was shown between groups in terms of the biochemical and immunohistochemical parameters. The histological examination of the regenerating liver tissue revealed the higher length density of sinusoids in the experimental group. CONCLUSION: Bevacizumab does not act to impair liver regeneration following hepatectomy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018572
003      
CZ-PrNML
005      
20250724124606.0
007      
ta
008      
220720s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12806 $2 doi
035    __
$a (PubMed)35478151
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Troup, Ondřej $u Department of Plastic Surgery, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic $7 xx0327816
245    10
$a Bevacizumab Does Not Inhibit the Formation of Liver Vessels and Liver Regeneration Following Major Hepatectomy: A Large Animal Model Study / $c O. Troup, A. Skalicky, L. Vistejnova, P. Klein, A. Maleckova, B. Florova, T. Malkus, J. Molacek, V. Treska, M. Kriz, J. Zeman, T. Skalicky
520    9_
$a BACKGROUND/AIM: Patients with unresectable liver colorectal cancer metastases are treated with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing the mass of metastases and thus increasing the chances of resectability. Bevacizumab comprises an anti-VEGF (vascular endothelial growth factor) humanized IgG monoclonal antibody that is used for biological therapy purposes. It acts to inhibit angiogenesis, thereby slowing down the growth of metastases. Due to its being administered systematically, bevacizumab also exerts an effect on the surrounding healthy liver parenchyma and potentially limits the process of neovascularization and thus regeneration of the liver. Since the remnant liver volume forms an important factor in postoperative morbidity and mortality following a major hepatectomy, we decided to study the effect of bevacizumab on vascular and biliary microarchitecture in healthy liver parenchyma and its ability to regenerate following major hepatectomy. MATERIALS AND METHODS: We performed an experiment employing a large animal model where a total of 16 piglets were divided into two groups (8 piglets in the control group and 8 piglets in the experimental group with bevacizumab). All the animals were subjected to major hepatectomy and the experimental group was given bevacizumab prior to hepatectomy. All the animals were sacrificed after 4 weeks. We performed biochemical analyses at regular time intervals during the follow-up period. Histological examination of the liver tissue was performed following sacrifice of the animals. RESULTS: No statistical difference was shown between groups in terms of the biochemical and immunohistochemical parameters. The histological examination of the regenerating liver tissue revealed the higher length density of sinusoids in the experimental group. CONCLUSION: Bevacizumab does not act to impair liver regeneration following hepatectomy.
650    _2
$a zvířata $7 D000818
650    _2
$a humanizované monoklonální protilátky $x farmakologie $x terapeutické užití $7 D061067
650    _2
$a bevacizumab $x farmakologie $x terapeutické užití $7 D000068258
650    12
$a kolorektální nádory $x farmakoterapie $x patologie $x chirurgie $7 D015179
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a hepatektomie $7 D006498
650    _2
$a lidé $7 D006801
650    12
$a nádory jater $x farmakoterapie $x sekundární $x chirurgie $7 D008113
650    _2
$a regenerace jater $7 D008115
650    _2
$a patologická angiogeneze $x farmakoterapie $7 D009389
650    _2
$a prasata $7 D013552
650    _2
$a vaskulární endoteliální růstový faktor A $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skalicky, Adam $u Department of Plastic Surgery, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Vistejnova, Lucie $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Klein, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Maleckova, Anna $u European Centre of Excellence NTIS, Faculty of Applied Sciences, University of West Bohemia, Pilsen, Czech Republic
700    1_
$a Florova, Blanka $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Malkus, Tomáš $u Department of Radiology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic $7 xx0334259
700    1_
$a Molacek, Jiri $u Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Treska, Vladislav $u Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Kriz, Miroslav $u First Department of Internal Medicine, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Zeman, Jan $u Department of Orthopedics and Traumatology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Skalicky, Tomas $u Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic; skalickya@fnplzen.cz
773    0_
$w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 36, č. 3 (2022), s. 1083-1094
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35478151 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20250724124546 $b ABA008
999    __
$a ok $b bmc $g 1822261 $s 1169815
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 3 $d 1083-1094 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20220720
Back

Find record

Citation metrics

Archiving options